Revaprazan

Revaprazan

Systematic (IUPAC) name
N-(4-Fluorophenyl)-4,5-dimethyl-6-(1-methyl-3,4-dihydro-2(1H)-isoquinolinyl)-2-pyrimidinamine
Clinical data
Trade names	Revanex[1]
Identifiers
CAS Number	199463-33-7
ATC code	None
PubChem	CID 204104
ChemSpider	176801
Synonyms	YH1885
Chemical data
Formula	C22H23FN4
Molar mass	362.44 g/mol
SMILES CC1C2=CC=CC=C2CCN1C3=NC(=NC(=C3C)C)NC4=CC=C(C=C4)F
InChI InChI=1S/C22H23FN4/c1-14-15(2)24-22(25-19-10-8-18(23)9-11-19)26-21(14)27-13-12-17-6-4-5-7-20(17)16(27)3/h4-11,16H,12-13H2,1-3H3,(H,24,25,26) Key:LECZXZOBEZITCL-UHFFFAOYSA-N

Revaprazan (trade name Revanex) is a drug that reduces gastric acid secretion which is used for the treatment of gastritis.^[2] It acts as an acid pump antagonist^[3] (potassium-competitive acid blocker). Revaprazan is approved for use in Korea,^[4] but is not approved in Europe or the United States.

References

1. "Revaprazan". drugs.com.
2. Kim HK, Park SH, Cheung DY, Cho YS, Kim JI, Kim SS, Chae HS, Kim JK, Chung IS (Oct 2010). "Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects". J Gastroenterol Hepatol 25 (10): 1618–1625. doi:10.1111/j.1440-1746.2010.06408.x. PMID 20880169.
3. Yu KS, Bae KS, Shon JH, Cho JY, Yi SY, Chung JY, Lim HS, Jang IJ, Shin SG, Song KS, Moon BS (Jan 2004). "Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers". J Clin Pharmacol 44 (1): 73–82. doi:10.1177/0091270003261321. PMID 14681344.
4. "Revaprazan Yuhan registered, South Korea (gastritis)". R & D Focus Drug News. September 25, 2006.